Literature DB >> 30816475

circRNA‑CER mediates malignant progression of breast cancer through targeting the miR‑136/MMP13 axis.

Yikun Qu1, Penghui Dou2, Ming Hu1, Jian Xu1, Weibin Xia1, Hongmei Sun3.   

Abstract

Chondrocyte extracellular matrix‑related circular RNAs (circRNA‑CER) have been demonstrated to be involved in various diseases. However, its role in the development of human breast cancer is not clearly understood. The aims of the present study were to assess circRNA‑CER expression in paired cancer tissue and adjacent non‑tumor tissue from 24 patients with breast cancer, and to explore the roles and mechanisms by which circRNA‑CER mediates the malignant progression of breast cancer cells. The results revealed that circRNA‑CER and matrix metalloproteinase 13 (MMP13) were upregulated, whereas miR‑136 was downregulated in breast cancer tissues compared with adjacent non‑tumor tissues. In vitro silencing of circRNA‑CER using small interfering RNA (siRNA) had inhibitory effects on MCF‑7 breast cancer cell proliferation and migration, and similar results were obtained following overexpression of microRNA (miR)‑136 in MCF‑7 cells by transfection with miR‑136 mimics. The subsequent mechanistic study revealed that the expression levels of MMP13 were significantly lower in MCF‑7 cells following transfection with miR‑136 mimics, and silencing of circRNA‑CER enhanced miR‑136 and decreased MMP13 expression levels. Furthermore, silencing of miR‑136 by transfection with miR‑136 inhibitors resulted in an increase in MCF‑7 cell proliferation and migration. miR‑136 inhibitor‑derived biological effects were reversed by co‑transfection of cells with miR‑136 inhibitors and circRNA‑CER siRNA. Taken together, the present results suggested that circRNA‑CER may serve an important role in the progression of breast cancer by regulating the activity of the miR‑136/MMP13 axis, and may be a potential biomarker for the prediction and treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30816475     DOI: 10.3892/mmr.2019.9965

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Circ_0069718 promotes the progression of breast cancer by up-regulating NFIB through sequestering miR-590-5p.

Authors:  Yongsheng Zhao; Xiaocha Ma; Weihua Shi
Journal:  Mamm Genome       Date:  2021-10-10       Impact factor: 2.957

2.  Circ_0008717 Sponges miR-326 to Elevate GATA6 Expression to Promote Breast Cancer Tumorigenicity.

Authors:  Ling Yang; Yuxin Chen
Journal:  Biochem Genet       Date:  2022-08-24       Impact factor: 2.220

3.  The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.

Authors:  Juan Xu; Xiyi Chen; Yu Sun; Yaqian Shi; Fang Teng; Mingming Lv; Chen Liu; Xuemei Jia
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

4.  CircNRIP1 Modulates the miR-515-5p/IL-25 Axis to Control 5-Fu and Cisplatin Resistance in Nasopharyngeal Carcinoma.

Authors:  Junwu Lin; Hong Qin; Yue Han; Xinghua Li; YuJuan Zhao; Guangsheng Zhai
Journal:  Drug Des Devel Ther       Date:  2021-01-27       Impact factor: 4.162

Review 5.  The Potential Role of N6-Methyladenosine (m6A) Demethylase Fat Mass and Obesity-Associated Gene (FTO) in Human Cancers.

Authors:  Jin-Yan Wang; Li-Juan Chen; Ping Qiang
Journal:  Onco Targets Ther       Date:  2020-12-15       Impact factor: 4.147

6.  Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198.

Authors:  Jin-Xiu Zhong; Yun-Yuan Kong; Rong-Guang Luo; Guo-Jin Xia; Wen-Xing He; Xue-Zhong Chen; Wei-Wei Tan; Qing-Jie Chen; Yu-Yin Huang; Yan-Xing Guan
Journal:  J Transl Med       Date:  2021-11-03       Impact factor: 5.531

Review 7.  The biogenesis, function and clinical significance of circular RNAs in breast cancer.

Authors:  Yan Zeng; Yutian Zou; Guanfeng Gao; Shaoquan Zheng; Song Wu; Xiaoming Xie; Hailin Tang
Journal:  Cancer Biol Med       Date:  2021-06-10       Impact factor: 4.248

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.